Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;21(1):127-137.
doi: 10.1080/14796694.2024.2421737. Epub 2024 Nov 15.

Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors

Arafat Tfayli  1 , Hady Ghanem  2 , Fadi Nasr  3 , Hampig Raphael Kourie  3 , Georges El Hachem  4 , Jamil Debs  5 , Sarah Masri  5 , Hazem I Assi  6 , Rosario García Campelo  7 , Joseph Kattan  3
Affiliations
Review

Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors

Arafat Tfayli et al. Future Oncol. 2025 Jan.

Abstract

Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical outcomes. In Lebanon, translating recommendations into clinical practice remains challenging. A Lebanese expert panel of oncologists was convened to describe the management paradigm and the clinical evidence supporting the optimal use of next-generation TKIs in patients with ALK-rearranged NSCLC and to provide an expert overview of local challenges and recommendations for optimizing the management of advanced NSCLC in Lebanese patients. The experts agreed that these recommendations should be part of a healthcare strategy to be implemented at the national level.

Keywords: ALK-rearrangement; ALK-tyrosine kinase inhibitor; expert opinion; lung cancer; non-small-cell lung cancer.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE uniform disclosure form.

A Tfayli: received honoraria from Pfizer Inc. as advisory board member. No additional disclosures.

H Ghanem: received honoraria from Pfizer Inc. as advisory board member and has participated as a speaker and consultancy for BMS, Astellas, Takeda, Pfizer, Lilly, Bayer, Janssen, BMS.

F Nasr: received honoraria from Pfizer Inc. as advisory board member and has participated as a speaker in symposiums with Pfizer, Lilly, Servier, Janssen, MSD, BMS.

HR Kourie: received honoraria from Pfizer Inc. as advisory board member and has participated as a speaker with Pfizer, Astrazeneca, Roche, Amgen, Merck, MSD, BMS, Eli Lilly, New Bridge, Astellas, Janssen and Novartis.

G El Hachem: received honoraria from Pfizer Inc. as advisory board member and has participated in advisory boards for Janssen, Merck, Astrazeneca and Amgen.

J Debs: Pfizer employment.

S Masri: Pfizer employment.

HI Assi: received honoraria from Pfizer Inc. as advisory board member. No additional disclosures.

RG Campelo: Received honoraria from Pfizer Inc. as advisory board speaker.

Advisory boards: MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda.

Consultancy: MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda.

Speaker honoraria: MSD, Bristol-Myers, Roche, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Lilly, Takeda.

J Kattan: received honoraria from Pfizer Inc. as advisory board member and has participated in advisory boards for Amgen, MSD, Merck, Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small-cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194. doi:10.1016/j.critrevonc.2020.103194 - DOI - PubMed
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small-cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature25183 - DOI - PubMed
    1. Hofman P. ALK in non-small-cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. Cancers (Basel). 2017;9(8):107. doi:10.3390/cancers9080107 - DOI - PMC - PubMed
    1. Rosas G, Ruiz R, Araujo JM, et al. . ALK rearrangements: biology, detection and opportunities of therapy in non-small-cell lung cancer. Crit Rev Oncol Hematol. 2019;136:48–55. doi:10.1016/j.critrevonc.2019.02.006 - DOI - PubMed

MeSH terms

Substances

Grants and funding